HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype

AIDS

Volumn 27, Issue 10, 2013, Pages 1535-1544

  Mabuka, Jennifer ^a,b   Goo, Leslie ^a,b   Omenda, Maxwel M ^a,b   Nduati, Ruth ^c   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; HETEROSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEWBORN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VERTICAL TRANSMISSION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEUTRALIZATION TESTS;

EID: 84879111348     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835faba5     Document Type: Article

References (40)

1. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4:316-319.
2. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.
3. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-409.
4. Kramer VG, Siddappa NB, Ruprecht RM. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 2007; 5:642-655.
5. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-W23.
6. Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679-689.
7. UNAIDS. Report on global HIV/AIDS epidemic. Geneva, Switzerland: UNAIDS; 2010.
8. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010; 6:e01001028.
9. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
10. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Olivera TYK, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-1637.
11. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
12. Hessell AJ, Poignard P, Hunter M, Hangartner L, TehraniF DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
13. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011; 334:1289-1293.
14. Walker L. Broad and potent neutralizing antibodies from an African donor reveals a new HIV-1 vaccine target. Science 2009; 326:285-289.
15. Doores KJ, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1 neutralizing antibodies PG9 and PG16. J Virol 2010; 84:10510-10521.
16. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480:336-343.
17. Walker LM, Huber M, DooresF KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
18. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334:1097-1103.
19. Wu X, Yang Z-Y, Li Y, Hogerkor CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-861.
20. Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol 2012; 86:3393-3397.
21. Euler Z, BunnikF EM, Burger JA, Boeser-Nunnink BDM, Grijsen ML, Prins JM, et al. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol 2011; 85:7236-7245.
22. Goo L, Jalalian-Lechak Z, Richardson BA, Overbaugh J. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J Virol 2012; 86:10857-10861.
23. Sagar M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis 2010; 202 (Suppl 2):S289-S296.
24. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303:2019-2022.
25. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81:6187-6196.
26. Wu X, ParastF AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80:835-844.
27. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol 2006; 80:6525-6533.
28. Zhang H, Tully DC, Hoffmann FG, He J, Kankasa C, Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS One 2010; 5:e9294.
29. Baan E, De Ronde A, Luchters S, Vyankandondera J, Lange JM, Pollakis G, et al. HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein. AIDS Res Hum Retroviruses 2011; 28:715-724.
30. Bansal P. A summary of the workshop onpassive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006. Biologicals 2007; 4:367-371.
31. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010:CD008440.
32. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-1174.
33. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012; 8:e1002739.
34. Voronin Y, Chohan B, Emerman M, Overbaugh J. Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood. J Virol 2007; 81:10232-10241.
35. Blish C, Nedellec R, Mandaliya K, Mosier D, Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007; 21:693-702.
36. Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, DoganF OC, Overbaugh J. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol 2009; 83:7783-7788.
37. Kliks SC, Wara DW, Landers DV, Levy JA. Features of HIV-1 that could influence maternal-child transmission. JAMA 1994; 272:467-474.
38. Zhang H, Rola M, West JT, Tully DC, Kubis P, He J, et al. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology 2010; 400:164-174.
39. Doria-Rose NA, Georgiev I, O'Dell S, Chuang GY, Staupe RP, McLellan JS, et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 2012; 86:8319-8323.
40. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18:1688-1692.